News Related to Complete Metabolic Response

Related coverage linked through entity extraction aliases.

Lantern Pharma Announces FDA Orphan Drug Designation for LP-284 and USPTO Patent Allowance for LP-184

Jul 24, 2026

Lantern Pharma's LP-284 received FDA Orphan Drug Designation for soft tissue sarcomas, while the USPTO allowed a patent for biomarker-guided use of LP-184 in multiple cancers. LP-284 showed a complete metabolic response in a Phase 1 DLBCL patient, and LP-184 demonstrated a 45% disease control rate in advanced solid tumors.

Real-World CAR T-Cell Therapy Outcomes Match Clinical Trial Results in Lymphoma

Mar 13, 2026

Real-world data from over 300 large B-cell lymphoma patients treated with axicabtagene ciloleucel show response rates and survival outcomes remarkably similar to pivotal trial results, with 86% overall response rate and 74% one-year survival.